Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 215

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 8
Chunk 215
---
 Statements of Cash Flows

(in thousands)

Year Ended December 31, 202420232022Cash flows from operating activities   Net earnings$73,865 $1,316 $60,711 Adjustments to reconcile net earnings to net cash provided by operating activities:Depreciation and amortization80,414 84,859 85,543 Other income from Navitor (see Note 4)— — (12,888)Intangible asset impairment charges— 20,189 — Amortization of deferred financing costs and debt discount— 532 2,112 Realized gains from sales of marketable securities(9)— (14)Amortization of premium/discount on marketable securities1,823 (122)3,233 Change in fair value of contingent consideration(6,110)(1,517)(510)Share-based compensation expense27,755 26,759 17,568 Deferred income tax benefit(20,136)(25,714)(26,324)Inventory valuation write-down8,876 8,023 10,442 Other noncash adjustments, net7,525 5,897 1,196 Changes in operating assets and liabilities:Accounts receivable2,078 18,765 (16,366)Inventories15,806 6,110 (17,858)Prepaid expenses and other assets(19,352)(334)12,303 Accrued product returns and rebates14,431 2,609 18,941 Accounts payable and other liabilities(15,015)(36,287)(19,163)Payment of contingent consideration— — (2,100)Net cash provided by operating activities171,951 111,085 116,826 Cash flows from investing activitiesPurchases of marketable securities(688,013)(101,621)(406,990)Maturities of marketable securities498,871 370,901 190,739 Purchases of property and equipment(725)(551)(412)Net cash provided by (used in) investing activities(189,867)268,729 (216,663)Cash flows from financing activitiesProceeds from Credit Line— 93,000 — Payments on Credit Line— (93,000)— Payment on convertible notes— (402,500)— Proceeds from issuance of common stock14,908 6,610 12